

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>OXFORD BIOSCIENCE PARTNERS IV LP</u>  (Last) (First) (Middle) 222 BERKELEY STREET  (Street) BOSTON MA 02116  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 05/26/2004	3. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC [ ACAD ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series F Convertible Preferred Stock	(1)	(2)	Common Stock	2,291,667	(3)	D <sup>(4)</sup>	
Series F Convertible Preferred Stock	(1)	(2)	Common Stock	23,148	(3)	I <sup>(5)</sup>	See footnote

1. Name and Address of Reporting Person* <u>OXFORD BIOSCIENCE PARTNERS IV LP</u>  (Last) (First) (Middle) 222 BERKELEY STREET  (Street) BOSTON MA 02116  (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>MRNA FUND II LP</u>  (Last) (First) (Middle) 222 BERKELEY STREET  (Street) BOSTON MA 02116  (City) (State) (Zip)
---

1. Name and Address of Reporting Person* <u>OBP MANAGEMENT IV LP</u>  (Last) (First) (Middle) 222 BERKELEY STREET  (Street) BOSTON MA 02116  (City) (State) (Zip)
--

1. Name and Address of Reporting Person\*

FLEMING JONATHAN

(Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

BARNES JEFFREY T

(Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

CARTHY MARK

(Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

LYTTON MICHAEL

(Last) (First) (Middle)

222 BERKELEY STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

**Explanation of Responses:**

1. Immediately
2. These securities are preferred stock of the issuer and do not have an expiration date.
3. 1-for-1
4. Securities held of record by Oxford Bioscience Partners IV L.P. ("OBP IV"). By virtue of their relationship as affiliated limited partnerships who share a general partner, mRNA Fund II L.P. ("mRNA") may be deemed to beneficially own the shares held of record by OBP IV. OBP Management IV L.P., as the general partner of OBP IV and mRNA may be deemed to beneficially own the shares held of record by OBP IV. Messrs. Fleming, Barnes, Carthy and Lytton as individual general partners of OBP Management IV L.P. may be deemed to beneficially own the shares held of record by OBP IV. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
5. Securities held of record by mRNA. By virtue of their relationship as affiliated limited partnerships who share a general partner, OBP IV may be deemed to beneficially own the shares held of record by mRNA. OBP Management IV L.P., as the general partner of OBP IV and mRNA may be deemed to beneficially own the shares held of record by mRNA. Messrs. Fleming, Barnes, Carthy and Lytton as individual general partners of OBP Management IV L.P. may be deemed to beneficially own the shares held of record by mRNA. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

**Remarks:**

Oxford Bioscience Partners IV L.P. By: Jonathan Fleming 05/26/2004  
mRNA Fund II LP, By: Jonathan Fleming 05/26/2004  
OBP Management IV LP, By: Jonathan Fleming 05/26/2004  
Jonathan J. Fleming 05/26/2004  
Jeffrey T. Barnes 05/26/2004  
Mark P. Carthy 05/26/2004  
Michael E. Lytton 05/26/2004

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

